GI CONNECT has summarised the highlights of ESMO 2016 for you.
Cancers of the upper GI tract by Dr. Dominik Modest
GI CONNECT has summarised the highlights of ESMO 2016 for you.
Cancers of the upper GI tract by Dr. Dominik Modest
Prof. Dr Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, after 10 years at the LMU in Munich, Germany, he is a physician at the Charité Universitaetsmedizin Berlin, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Prof. Dr Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy and a full professorship in 2020. Prof. Dr Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.
Servier, Amgen, Merck, Sanofi, Lilly, BMS, MSD, AstraZeneca, Pierre Fabre, GSK, Seagen, G1, Onkowissen, COR2ED, Taiho, Takeda, Incyte, Cureteq, 21up, IKF, Medscape, Aptitude Health, Bicara, Rottapharm, Agenus, Regeneron, AIO gGmbH
Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO
Expert opinion on the latest practice-changing data
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului
Improving the survival of patients with relapsed/refractory multiple myeloma